Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherReceivables RefundsShares OutstandingShares OutstandingShort-Term Debt repayments
Ratios

BioNexus Gene Lab (BGLC) Shares Outstanding (2018 - 2025)

BioNexus Gene Lab's Shares Outstanding history spans 8 years, with the latest figure at $2.4 million for Q4 2025.

  • Quarterly results put Shares Outstanding at $2.4 million for Q4 2025, up 34.54% from a year ago — trailing twelve months through Dec 2025 was $2.4 million (up 34.54% YoY), and the annual figure for FY2025 was $2.4 million, up 34.54%.
  • Shares Outstanding for Q4 2025 was $2.4 million at BioNexus Gene Lab, up from $1.8 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $173.7 million in Q3 2022 to a low of $1.8 million in Q4 2023.
  • The 5-year median for Shares Outstanding is $14.5 million (2022), against an average of $57.9 million.
  • The sharpest move saw Shares Outstanding plummeted 91.67% in 2021, then surged 1117.52% in 2023.
  • Year by year, Shares Outstanding stood at $14.3 million in 2021, then increased by 1.46% to $14.5 million in 2022, then crashed by 87.8% to $1.8 million in 2023, then grew by 1.7% to $1.8 million in 2024, then surged by 34.54% to $2.4 million in 2025.
  • According to Business Quant data, Shares Outstanding over the past three periods came in at $2.4 million, $1.8 million, and $1.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.